At the 2026 American College of Cardiology (ACC) Scientific Session in New Orleans, investigators from Brazil presented a systematic review and meta-analysis of randomized controlled trials evaluating lorundrostat in patients with uncontrolled hypertension on background therapy. The analysis included three placebo-controlled trials with a total of 1,060 patients and focused on blood pressure reduction and safety outcomes.
Current hypertension guidelines recommend mineralocorticoid receptor antagonists for patients with uncontrolled blood pressure, but their use is often limited by adverse events such as hyperkalemia and worsening kidney function. As a result, many patients with persistent hypertension despite combination therapy have restricted options, and there is interest in more targeted approaches to aldosterone-driven disease.
Go deeper with GlobalData
Lorundrostat is a selective aldosterone synthase inhibitor that directly reduces aldosterone biosynthesis, aiming to provide blood pressure lowering while improving tolerability compared with traditional mineralocorticoid receptor antagonists. In the meta-analysis, lorundrostat 50 mg reduced systolic blood pressure by 9.08 mm Hg versus placebo, and the 100 mg dose reduced systolic blood pressure by 11.41 mm Hg. Diastolic blood pressure also decreased with lorundrostat 50 mg, with a mean reduction of 3.48 mm Hg, and heterogeneity across trials was low, supporting consistency of effect.
Safety findings highlighted an increased risk of hyperkalemia with lorundrostat at both studied doses. Hyperkalemia events were more frequent in the lorundrostat groups than with placebo, and the risk was higher at 100 mg than at 50 mg, indicating that higher doses will likely require closer potassium monitoring and may not be suitable for all patients. No additional safety details are provided in the abstract, but the pattern suggests that any future use of lorundrostat will need clear monitoring strategies and patient selection criteria.
Experts are likely to see these data as evidence that lorundrostat can deliver meaningful additional blood pressure reduction in uncontrolled hypertension, while also reinforcing that aldosterone-targeted strategies carry a predictable risk of hyperkalemia. KOLs will probably focus on how lorundrostat compares with mineralocorticoid receptor antagonists in routine practice, and which subgroups with lower baseline potassium or preserved kidney function might achieve the best balance of benefit and risk.
From a strategic perspective, these results support lorundrostat as a potential late-line add-on option in uncontrolled or resistant hypertension rather than a broad alternative to low-cost first-line therapies. The size of the systolic blood pressure reduction is competitive, but the hyperkalemia signal is likely to drive cautious uptake and make risk mitigation, monitoring protocols, and differentiation from generic mineralocorticoid receptor antagonists central to any launch strategy.
Looking ahead, larger phase III trials and long-term safety studies will be needed to clarify lorundrostat’s role in real-world treatment pathways, including its use in patients with chronic kidney disease or other high-risk features. If future data show that careful patient selection and monitoring can manage hyperkalemia while sustaining blood pressure benefits, lorundrostat could secure a place in resistant hypertension algorithms, but without clear safety or operational advantages it may remain a focused option within a crowded antihypertensive landscape.
